B1

1. (Twice Amended) A method of treating glycogen storage disease type II in a human individual having glycogen storage disease type II, comprising administering to the individual a therapeutically effective amount of human acid α-glucosidase periodically at an administration interval, wherein the human acid α-glucosidase was produced in chinese hamster ovary cell cultures.

11. (Amended) The method of Claim 1, wherein the administration interval is monthly.

B2

12. (Amended) The method of Claim 1, wherein the administration interval is bimonthly.

13. (Amended) The method of Claim 1, wherein the administration interval is weekly.

14. (Amended) The method of Claim 1, wherein the administration interval is twice weekly.

15. (Amended) The method of Claim 1, wherein the administration interval is daily.

B3

21. (Twice Amended) A method of treating cardiomyopathy associated with glycogen storage disease type II in a human individual having glycogen storage disease type II, comprising administering to the individual a therapeutically effective amount of human acid α-glucosidase periodically at an administration interval, wherein the human acid α-glucosidase was produced in chinese hamster ovary cell culture

22. (Twice Amended) A pharmaceutical composition comprising human acid α-glucosidase, wherein the human acid α-glucosidase was produced in chinese hamster ovary cell culture, in a container, the container having a label containing instructions for administration of the composition for treatment of glycogen storage disease type II.

Please add Claim 23:

B4

23. (New) The method of Claim 1, wherein the administration interval is varied over time.